Evaluating treatment recommendations for children with nephroblastoma
Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.
This study looks at how well hospitals follow treatment guidelines for children with nephroblastoma who haven't had treatment yet, to see if sticking to these guidelines leads to better outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 6 Months to 18 Years |
| Sex | All |
| Sponsor | French Africa Pediatric Oncology Group Academic / other |
| Locations | 7 sites (Ouagadougou and 6 other locations) |
| Trial ID | NCT04423484 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how well medical units adhere to treatment recommendations for nephroblastoma based on findings from two previous studies by the GFAOP. It will focus on treatment compliance and outcomes for children diagnosed with unilateral nephroblastoma who have not received prior treatment. The study will also evaluate improvements in treatment compliance and reporting, which will help tailor future treatment programs to local conditions and needs.
Who should consider this trial
Good fit: Ideal candidates are children with unilateral nephroblastoma who have not been previously treated and are in good general health.
Not a fit: Patients with bilateral nephroblastoma, those who have been previously treated, or those with advanced disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment compliance and outcomes for children with nephroblastoma.
How similar studies have performed: While this study builds on previous research, its specific approach to evaluating treatment compliance is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment. . Exclusion Criteria: Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal
Where this trial is running
Ouagadougou and 6 other locations
- Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle — Ouagadougou, Burkina Faso (Recruiting)
- CHU de Treichville à ABIDJAN — Abidjan, Abidjan Autonomous District, Côte d’Ivoire (Recruiting)
- CUK (Cliniques Universitaires de Kinshasa) — Kinshasa, Democratic Republic of the Congo (Recruiting)
- Cliniques Universitaires de Lubumbashi (CUL) — Lubumbashi, Democratic Republic of the Congo (Recruiting)
- HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona — Antananarivo, Madagascar (Recruiting)
- CHU Gabriel Touré (HGT) — Bamako, Mali (Recruiting)
- Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001 — Dakar, Dakar, Senegal (Recruiting)
Study contacts
- Principal investigator: Fatou Binetou Ms DIAGNE AKONDE, Dr — French Africa Pediatric Oncology Group
- Study coordinator: BRENDA Ms MALLON, MSC
- Email: brenda.mallon@gustaveroussy.fr
- Phone: 0033142115411
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.